Literature DB >> 20470203

Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer.

Carole Spencer1, Shireen Fatemi, Peter Singer, John Nicoloff, Jonathan Lopresti.   

Abstract

BACKGROUND: Recombinant human thyrotropin (rhTSH) stimulation is frequently used to assess the disease status of patients treated for differentiated thyroid cancer (DTC) when basal (unstimulated) thyroglobulin (b-Tg) is below the assay sensitivity limit. The objective of this study was to determine relationships between the b-Tg and the 72-hour rhTSH-stimulated Tg (rhTSH-Tg) using a second-generation immunochemiluminometric assay with a functional sensitivity of 0.05 ng/mL (microg/L).
METHODS: Serum Tg was measured in paired b-Tg and rhTSH-Tg specimens from 1029 rhTSH tests performed on 849 TgAb-negative patients during long-term monitoring for DTC.
RESULTS: Basal Tg correlated with rhTSH-Tg across b-Tg concentrations ranging from 0.05 to 1000 ng/mL (microg/L) (r = 0.85, p < 0.0001). The b-Tg concentration was unrelated to age, sex, basal TSH, 72-hour TSH, or the Tg fold response (rhTSH-Tg/b-Tg). Further, only 2/655 (0.3%) tests with b-Tg below 0.1 ng/mL (microg/L) had rhTSH-Tg above 2.0 ng/mL (microg/L) (2.9 and 3.8 ng/mL [microg/L], respectively). Thirty-three patients with three or more rhTSH tests performed over a 2- to 5-year period displayed high indexes of individuality for both the 72-hour TSH and the Tg fold response (indexes of individuality = 0.30 and 0.38, respectively). Basal Tg measured using a first-generation assay with a functional sensitivity of 0.9 ng/mL (microg/L) failed to reliably detect an rhTSH-Tg response above 2.0 ng/mL (microg/L).
CONCLUSIONS: An rhTSH-Tg response above 2.0 ng/mL (microg/L) was highly unlikely when b-Tg was below 0.1 ng/mL (microg/L). Second-generation b-Tg measurements correlated with the degree of rhTSH-Tg stimulation and thus the likelihood of having rhTSH-Tg above the customary cut-off of 2.0 ng/mL (microg/L), whereas b-Tg measured by a first-generation assay did not. Correlations between four different assays showed that the use of a fixed Tg cut-off was influenced by assay selection. Patients receiving repetitive rhTSH tests had highly reproducible rhTSH-Tg/b-Tg fold responses, suggesting that repetitive testing is unnecessary and that second-generation measurement of b-Tg trends without rhTSH stimulation would be satisfactory for the long-term monitoring of most patients with DTC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20470203     DOI: 10.1089/thy.2009.0338

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  23 in total

Review 1.  Controversies in the Management of Low-Risk Differentiated Thyroid Cancer.

Authors:  Megan R Haymart; Nazanene H Esfandiari; Michael T Stang; Julia Ann Sosa
Journal:  Endocr Rev       Date:  2017-08-01       Impact factor: 19.871

Review 2.  Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita
Journal:  Thyroid       Date:  2015-07       Impact factor: 6.568

Review 3.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

Review 4.  Thyroglobulin as a biomarker of iodine deficiency: a review.

Authors:  Zheng Feei Ma; Sheila A Skeaff
Journal:  Thyroid       Date:  2014-06-12       Impact factor: 6.568

5.  Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.

Authors:  Alberto S Tresoldi; Laura F Sburlati; Marcello Rodari; Mink S Schinkelshoek; Michela Perrino; Simone De Leo; Laura Montefusco; Paolo Colombo; Maura Arosio; Andrea Gerardo Antonio Lania; Laura Fugazzola; Arturo Chiti
Journal:  J Endocrinol Invest       Date:  2014-05-21       Impact factor: 4.256

6.  Basal serum thyroglobulin measured by a second-generation assay is equivalent to stimulated thyroglobulin in identifying metastases in patients with differentiated thyroid cancer with low or intermediate risk of recurrence.

Authors:  Cláudia C D Nakabashi; Teresa S Kasamatsu; Felipe Crispim; Claudia A Yamazaki; Cléber P Camacho; Danielle M Andreoni; Rosalia P Padovani; Elza S Ikejiri; Maria C O M Mamone; Flávia C Aldighieri; Jairo Wagner; Jairo T Hidal; José G H Vieira; Rosa P M Biscolla; Rui M B Maciel
Journal:  Eur Thyroid J       Date:  2014-03-12

7.  Clinical presentations of thyroid cancer patients with multiple primary cancers.

Authors:  J D Lin; K J Lin; T C Chao; C Hseuh; N M Tsang; B Y Huang
Journal:  J Endocrinol Invest       Date:  2011-05-24       Impact factor: 4.256

Review 8.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.

Authors:  Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky
Journal:  Thyroid       Date:  2016-01       Impact factor: 6.568

9.  In thyroidectomized patients with thyroid cancer, a serum thyrotropin of 30 μU/mL after thyroxine withdrawal is not always adequate for detecting an elevated stimulated serum thyroglobulin.

Authors:  Laticia A Valle; Revital L Gorodeski Baskin; Kyle Porter; Jennifer A Sipos; Raheela Khawaja; Matthew D Ringel; Richard T Kloos
Journal:  Thyroid       Date:  2013-02       Impact factor: 6.568

Review 10.  Clinical review: improving the measurement of serum thyroglobulin with mass spectrometry.

Authors:  Andrew N Hoofnagle; Mara Y Roth
Journal:  J Clin Endocrinol Metab       Date:  2013-02-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.